scholarly journals Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas

2021 ◽  
Vol 10 (1) ◽  
Author(s):  
Yingying Ye ◽  
Ning Ding ◽  
Lan Mi ◽  
Yunfei Shi ◽  
Weiping Liu ◽  
...  
Keyword(s):  
T Cell ◽  
Clinical Outcomes ◽  
T Cell Activation ◽  
Cell Activation ◽  
Cell Lymphoma ◽  
Negative Impact ◽  
Chromatin Modification ◽  
Progression Free Survival ◽  
Survival Outcome ◽  
T Cell Lymphoma

Abstract Objective To explore the correlation of mutation landscape with clinical outcomes in patients with peripheral T-cell lymphoma (PTCL). Methods We retrospectively analyzed the clinicopathological and prognosis data of 53 patients with PTCL from November 2011 to December 2017. Targeted next-generation sequencing of a 659-gene panel was performed for tissues from 53 patients with PTCLs. The correlation of mutation landscape with clinical outcomes was analyzed. Results TET2 was the most frequently mutated gene (64%), followed by RHOA (43%), PCLO (23%), DNMT3A (19%), IDH2 (17%), PIEZO1 (17%) and TP53 (15%). When mutated genes were categorized into functional groups, the most common mutations were those involved in epigenetic/chromatin modification (75%), T-cell activation (74%), and the DNA repair/TP53 pathway (64%). TET2/TP53 mutations were significantly associated with positive B symptoms (P = 0.045), and elevated lactate dehydrogenase (LDH) level (P = 0.011). Moreover, TET2/TP53 mutation was a risk factor for PTCL patient survival (HR 3.574, 95% CI 1.069 − 11.941, P = 0.039). The occurrence of JAK/STAT pathway mutations in angioimmunoblastic T-cell lymphoma (AITL) patients conferred a worse progression-free survival (HR 2.366, 95% CI 0.9130–6.129, P = 0.0334). Conclusions Heterogeneous gene mutations occur in PTCL, some of which have a negative impact on the survival outcome.

Clinical Outcomes of Patients with T Cell NHL Undergoing Allogeneic Stem Cell Transplant.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 3026-3026 ◽  
Author(s):  
Jasmine Zain ◽  
J. Palmer ◽  
N. Tsai ◽  
L. Popplewell ◽  
A. Nadamanee ◽  
...  
Keyword(s):  
Overall Survival ◽  
T Cell ◽  
B Cell ◽  
Sample Size ◽  
Clinical Outcomes ◽  
Cell Lymphoma ◽  
Progression Free Survival ◽  
T Cell Lymphoma ◽  
Cell Transplant ◽  
Free Survival

Abstract Background: T cell NHL represent approximately 10–15% of all lymphomas. Pts with T cell NHL are often treated similarly to patient with B cell NHL, although the clinical outcomes of most patients with T- NHL tend to be worse with the exception of ALK positive anaplastic large cell lymphomas (ALCL). Updated classifications in recent years have recognized specific clinical and pathologic T cell entities with distinct clinical courses and this poses a challenge to the systemic study of these diseases. The exact role of allogenic transplant in T- cell NHL is unknown. Methods: We looked at 45 pts who underwent an allogeneic HSCT for T cell lymphomas between Jan 2000 to Dec 2005. There were 18 males, 27 females. Median age at transplant was 32 (7–74). Histology was Mycosis fungoides /Sezary syndrome (SS/MF) n=10, T cell lymphobalstic leukemia (PTLL) n=16, PTCL including AILD and ALCL n=14, NKT cell n=5. Syngeneic donor 1, Sibs 31, MUD 13. Median time from diagnosis to transplant was 12.5 (3.6–88.3) mo. Source of stem cells BM 9, PBSCT 35, cord blood 1. Conditioning, fully ablative 29, reduced intensity 16. Median number of prior regimens MF/SS 5, PTLL 2, PTCL 3, NKTL 2 with only 2 pts with prior auto transplants. 18 pts were in remission at the time of transplant and 12 pts had induction failure. Results: Median follow up from transplant was 45.3 mo(0.7–64.7) with a 55.6%OS. Incidence of GVHD was Acute n= 27 extensive chronic n=20. Cause of death was transplant related in 16 pts with only 3 pts dying of disease progression. The overall survival is 61.2 % at 1 year,55.4% at 2 years and 48.5% at 5 years with a 5 year progression free survival at 48.5%. Based on different histologies, the results are 50.0% overall survival at 1 year and 40.0% at 2 and 5 years for SS/MF, 55.6% at 1 and 2 years for PTLL, 70.1% at 1 and 2 years and 52.6% at 5 years for PTCL and 80% at 1 year for NKT shown in fig 1 and 2. Conclusion: Allogenic transplant can result in long term survival for some patients with T cell NHL suggesting a graft vs lymphoma effect. Timing of transplant needs to be better defined. Most patients are heavily pretreated which may have resulted in more transplant related mortality with 11/20 pts dying of infection. Most patients did not have a prior auto transplant indicating early progression of disease after standard therapies defined for B cell malignancies. Overall Survival by Histology
 T-Cell Lymphoma with Allogenic Transplant
 Sample Size: 45 patients Overall Survival by Histology
 T-Cell Lymphoma with Allogenic Transplant
 Sample Size: 45 patients Progression-Free Survival by Histology
 T-Cell Lymphoma with Allogenic Transplant
 Sample Size: 45 patients Progression-Free Survival by Histology
 T-Cell Lymphoma with Allogenic Transplant
 Sample Size: 45 patients

scholarly journals Constitutive PSGL-1 Correlates with CD30 and TCR Pathways and Represents a Potential Target for Immunotherapy in Anaplastic Large T-Cell Lymphoma

Cancers ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 2958
Author(s):  
Beatrice Belmonte ◽  
Valeria Cancila ◽  
Alessandro Gulino ◽  
Mohsen Navari ◽  
Walter Arancio ◽  
...  
Keyword(s):  
T Cell ◽  
T Cell Activation ◽  
Cell Activation ◽  
Cell Lymphoma ◽  
Immunohistochemical Analysis ◽  
Cell Receptor ◽  
T Cell Lymphoma ◽  
Tcr Signaling ◽  
Potential Target

Due to the high expression of P-selectin glycoprotein ligand-1 (PSGL-1) in lymphoproliferative disorders and in multiple myeloma, it has been considered as a potential target for humoral immunotherapy, as well as an immune checkpoint inhibitor in T-cells. By investigating the expression of SELPLG in 678 T- and B-cell samples by gene expression profiling (GEP), further supported by tissue microarray and immunohistochemical analysis, we identified anaplastic large T-cell lymphoma (ALCL) as constitutively expressing SELPLG at high levels. Moreover, GEP analysis in CD30+ ALCLs highlighted a positive correlation of SELPLG with TNFRSF8 (CD30-coding gene) and T-cell receptor (TCR)-signaling genes (LCK, LAT, SYK and JUN), suggesting that the common dysregulation of TCR expression in ALCLs may be bypassed by the involvement of PSGL-1 in T-cell activation and survival. Finally, we evaluated the effects elicited by in vitro treatment with two anti-PSGL-1 antibodies (KPL-1 and TB5) on the activation of the complement system and induction of apoptosis in human ALCL cell lines. In conclusion, our data demonstrated that PSGL-1 is specifically enriched in ALCLs, altering cell motility and viability due to its involvement in CD30 and TCR signaling, and it might be considered as a promising candidate for novel immunotherapeutic approaches in ALCLs.

scholarly journals MALIGNANT T CELL ACTIVATION BY A BACILLUS SPECIES ISOLATED FROM CUTANEOUS T CELL LYMPHOMA LESIONS

2021 ◽  
pp. 100084
Author(s):  
Carina A. Dehner ◽  
William E. Ruff ◽  
Teri Greiling ◽  
Márcia S. Pereira ◽  
Sylvio Redanz ◽  
...  
Keyword(s):  
T Cell ◽  
T Cell Activation ◽  
Cell Activation ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Bacillus Species ◽  
Cutaneous T Cell Lymphoma

scholarly journals 1032 Glycolipid antigens presented by CD1 may drive T cell activation in cutaneous T cell lymphoma

2019 ◽  
Vol 139 (5) ◽  
pp. S178
Author(s):  
K.K. Yu ◽  
A. Vromans ◽  
J. Crouch ◽  
A. Gehad ◽  
J.E. Teague ◽  
...  
Keyword(s):  
T Cell ◽  
T Cell Activation ◽  
Cell Activation ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma

scholarly journals Phosphatase and tensin homolog (PTEN) is down-regulated in human NK/T-cell lymphoma and corrects with clinical outcomes

Medicine ◽  
2017 ◽  
Vol 96 (29) ◽  
pp. e7111 ◽  
Author(s):  
Xiaorui Fu ◽  
Xudong Zhang ◽  
Jinli Gao ◽  
Xin Li ◽  
Lei Zhang ◽  
...  
Keyword(s):  
T Cell ◽  
Clinical Outcomes ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Phosphatase And Tensin Homolog ◽  
Tensin Homolog ◽  
Nk T Cell

scholarly journals Decreased Cytokine Plasma Levels and Changes in T-Cell Activation Are Associated With Hemodynamic Improvement and Clinical Outcomes After Percutaneous Mitral Commissurotomy in Patients With Rheumatic Mitral Stenosis

2021 ◽  
Vol 7 ◽  
Author(s):  
Vicente R. Silva ◽  
Eula G. A. Neves ◽  
Lívia S. Araújo Passos ◽  
Flávia Cristina de Melo ◽  
Andrea Teixeira-Carvalho ◽  
...  
Keyword(s):  
T Cell ◽  
Adverse Events ◽  
Clinical Outcomes ◽  
T Cell Activation ◽  
Plasma Levels ◽  
Mitral Stenosis ◽  
Cell Activation ◽  
Hemodynamic Improvement ◽  
Mitral Commissurotomy

Mitral stenosis (MS) is a consequence of rheumatic heart disease that leads to heart failure requiring mechanical intervention. Percutaneous mitral commissurotomy (PMC) is the treatment of choice for the intervention, and currently there are no soluble markers associated with hemodynamic improvement after PMC. This study aims to determine the changes in cytokine/chemokine plasma levels, as well as T cell activation after PMC, and to investigate their association with immediate hemodynamic improvement and clinical outcomes. Plasma samples from eighteen patients with well-defined MS who underwent PMC and 12 healthy controls were analyzed using BioPlex immunoassay. We observed that 16 out of the 27 (60%) molecules assessed were altered in patients' plasma pre-PMC as compared to control group. Of those, IL-1β, IL-12, IL-6, IL-4, PDGF, and CCL11 showed significant decrease after PMC. Stratifying the patients according to adverse outcome after a 28-month median follow up, we detected a significant reduction of IL-1β, IL-12, IL-6, IL-4, IFN-γ, CXCL-10, VEGF, FGF and PDGF post-PMC in patients without events, but not in those who presented adverse events during the follow-up. Patients with adverse outcomes had lower IL-10 pre-PMC, as compared to the ones without adverse events. In addition, the frequency of CD8+ activated memory cells was increased after PMC, while the frequency of CD4+ activated memory cells did not change. Our results show an association between the decrease of specific cytokines and changes in T cell activation with hemodynamic improvement post-PMC, as well as with long-term outcomes, suggesting their possible use as soluble markers for hemodynamic recovery after MS intervention.

The Prevalence of CD30 Expression and Relationship to Survival in Patients with Peripheral T-Cell Lymphoma (PTCL)

2021 ◽  
Vol 104 (1) ◽  
pp. 52-58
Keyword(s):  
T Cell ◽  
Cox Regression ◽  
Cell Lymphoma ◽  
Survival Outcome ◽  
T Cell Lymphoma ◽  
Histological Subtypes ◽  
Peripheral T Cell Lymphoma ◽  
Cox Regression Analysis ◽  
Poor Survival Outcome ◽  
Tissue Specimens

Objective: To define the prevalence of CD30 expression and the relationship to survival in patients with peripheral T-cell lymphoma (PTCL). Materials and Methods: A 12-year retrospective study of 135 PTCL patients was completed. Their tissue specimens were stained for CD30 antibody and the results were correlated with clinical data and survival. Results: One hundred thirty-five patients were enrolled. The subtypes of PTCL were classified as PTCL-NOS (36.3%), nasal NKTCL (17.8%), AITL (15.6%), CTCL (13.3%), SPTCL (11.1%), ALCL (4.4%), C-ALCL (0.7%), and EATL (0.7%). The expression of CD30 in the PTCLs was 34.8%, which significantly associated with histological subtypes (p<0.001). There was a higher prevalence in ALCL or C-ALCL (100.0%), nasal NKTCL (79.2%), and PTCL- NOS (30.6%). The median survival was 25 months with a projected 5-year survival of 37.0%. CD30 positivity was significantly associated with poor survival outcome (CD30⁻ 30 months versus CD30⁺ 14 months, p=0.013). From Cox regression analysis, PTCL subtypes were independent prognostic predictor for survival in the present study. Conclusion: The expression of CD30 in PTCLs was demonstrated in one-third of patients and was associated with histological subtypes and inferior survival outcome. Keywords: CD30, Survival, Peripheral T-cell lymphoma

Sign in / Sign up

Export Citation Format

Share Document